Refractory pituitary adenoma is characterized by invasive tumor growth, continuous growth and/or hormone hypersecretion in spite of standardized multi-modal treatment such as surgeries, medications or radiations. Quality of life or even lives are threatened by these tumors. According to the 2017 World Health Organization's new classification guideline of pituitary adenoma, patients have to suffer from symptoms or complications caused by these tumors, to bear a heavy financial burden, and to accept additional therapeutic side effects when the diagnosis of "refractory pituitary adenoma" is made. If refractory pituitary adenoma could be predicted at early stage, these patients would be able to have a more frequent clinical follow-up, receive multiple effective treatment as early as possible, or even be enrolled in clinical trials of investigational medications, so as to prevent or delay the recurrence or persistent of the tumor growth. Therefore, the unmet clinical need falls into an early prediction system for refractory pituitary adenomas, which could provide accurate guidance for subsequent treatment in the early stage. The investigators have constructed a pituitary adenoma database including clinical data, radiological images, pathological images and genetic information. The investigators are proposing a study using machine learning to extract features from these multi-dimensional, multi-omics data, which could be further used to train a prediction model for the risk of refractory pituitary adenoma. The proposed model would also be validated in another prospectively collected database. The established model would be able to identify potential medication targets and provide guidance for personalized therapy of refractory pituitary adenoma.
Study Type
OBSERVATIONAL
Enrollment
1,000
Results of artificial intelligence model will be compared with the gold standard
Huashan Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGThe risk of refractory pituitary adenoma
Predicting the development of refractory pituitary adenoma after the first surgery
Time frame: 10 years
Predicting Gamma Knife efficacy
Predicting endocrine remission after Gamma Knife surgery in Growth Hormone secreting pituitary adenoma
Time frame: 5 years
Predicting immunostaining
Predicting immunostaining in patients with non-functioning pituitary adenoma using H\&E stained images
Time frame: Two weeks after surgery
Predicting recurrence
Predicting relapse or regrowth of a non-functioning pituitary adenoma after the first surgery
Time frame: 10 years
Predicting endocrinopathy
Predicting endocrinopathy which warrant replacement after pituitary adenoma resection
Time frame: 10 years
Predicting surgical difficulty and complications
Predicting surgical difficulty and complications using pre-surgical radiomic features
Time frame: Two weeks after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.